Rindler, Katharina
Jonak, Constanze
Alkon, Natalia
Thaler, Felix M.
Kurz, Harald
Shaw, Lisa E.
Stingl, Georg
Weninger, Wolfgang
Halbritter, Florian
Bauer, Wolfgang M.
Farlik, Matthias
Brunner, Patrick M. http://orcid.org/0000-0002-3488-3345
Funding for this research was provided by:
Austrian Science Fund (KLI 849-B)
Article History
Received: 26 May 2021
Accepted: 28 August 2021
First Online: 28 September 2021
Declarations
:
: The study was conducted under a protocol approved by the Ethics Committee of the Medical University of Vienna, Austria (EK 1360/2018).
: Not applicable.
: CJ is an employee of the Medical University of Vienna, and has received personal fees from LEO Pharma, Pfizer, Recordati Rare Diseases, Eli Lilly and Company, Novartis, Takeda, Mallinckrodt/Therakos, AbbVie, Janssen, Sandoz, Kyowa Kirin and Almirall independently from this work. CJ is an investigator for Eli Lilly and Company, LEO Pharma, Novartis, and 4SC (grant paid to her institution). GS received personal fees from Boehringer Ingelheim, Sanofi-Genzyme, Almirall, and Novartis. WW is an employee of the Medical University of Vienna and has received personal fees from LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Boehringer Ingelheim, AbbVie, and Janssen. WMB is an employee of the Medical University of Vienna and has received personal fees from Takeda, Abbvie, GSK/ViiV and Gilead. PMB is an employee of the Medical University of Vienna, and has received personal fees from LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Celgene, UCB Pharma, Biotest, Boehringer Ingelheim, AbbVie, Amgen, Arena Pharmaceuticals, GSK and Regeneron independently from this work. PMB is an investigator for Novartis (grant paid to his institution). The rest of the authors declare that they have no relevant conflicts of interest.